Insmed Inc splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was BRINSUPRI at $400.1 million, 76% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,520
|
524
|
425
|
306
|
264
|
142
|
107
|
93
|
104
|
| BRINSUPRI |
1,062
share 69.9%
|
400
+1326.2%
share 76.3%
|
309
share 72.7%
|
208
share 67.9%
|
145
share 54.8%
|
28
share 19.7%
|
—
|
—
|
—
|
| ARIKAYCE |
458
+9.3%
share 30.1%
|
124
+8.8%
share 23.7%
|
116
+8.3%
share 27.3%
|
98
+5.7%
share 32.1%
|
119
+14.2%
share 45.2%
|
114
share 80.3%
|
107
share 100.0%
|
93
share 100.0%
|
104
share 100.0%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INSM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Bridgewater, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1104506
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.